Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) shares fell 13.7% during trading on Friday. The stock traded as low as $5.05 and last traded at $5.05. 1,020 shares were traded during mid-day trading, a decline of 35% from the average session volume of 1,570 shares. The stock had previously closed at $5.85.
Starpharma Trading Down 13.7%
The firm has a fifty day moving average of $5.23 and a two-hundred day moving average of $4.75.
Starpharma Company Profile
Starpharma Holdings Limited is an Australian biotechnology company focused on developing medicines and healthcare products using its proprietary dendrimer technology. Dendrimers are highly branched molecules that can be engineered for applications including drug delivery, antiviral treatment and targeted therapies.
The company’s lead product is astodrimer sodium, also known as SPL7013, which was developed as a non-antibiotic treatment for bacterial vaginosis under the VivaGel brand. Starpharma has also investigated the compound and related dendrimer technologies for antiviral applications, including products designed to help prevent or reduce viral infection.
Starpharma has entered licensing and commercialization arrangements for selected products and technologies in international markets.
Read More
- Five stocks we like better than Starpharma
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
